Pneumocystis Cariinii 29 2 2013

Embed Size (px)

Citation preview

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    1/20

    Pneumocystis cariniiDisease: Pneumocystosis

    RECENTLY BEEN PLACED IN A GROUP

    OF FUNGI ENTITLED THE

    ARCHIA SCOMYCETES

    Late century - protozoa

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    2/20

    Whats in a name?

    Pneumocystis jiroveci (previously known asPneumocystis carinii) is an unusual opportunistic

    organism, which causes a severe and often fatal

    pneumonia in immunocompromised individuals.

    Discovered in 1909 by Chagas (in guinea pigs) & in1910 by Carini (in rats).

    In honor of Carini, named P carinii in 1912

    Identified in humans (premature and malnourishedkids) in 1952 by Otto Jirovec

    Species that affect humans renamed P jiroveci in

    2001/2002

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    3/20

    RESERVOIR P.carinniis widespread in nature and

    occurs in many mammals

    Other mammals:

    Pneumocystis jirovecii

    Humans YOU

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    4/20

    CYSTS In BAL Material

    The cystic form (sporangium) is

    thick-walled oval, approximately5 to 8 in diameter

    Contain up to eight daughter

    forms (spores or endospores,

    formerly known as intracystic

    bodies or sporozoites), which

    will become trophic

    forms after excystation.

    TROPHOZOITE in BAL

    Material

    The trophic form (yeast,

    formerly trophozoite)

    is small (2 to 5m), thin-walled,

    pleomorphic and often has

    an eccentric nucleus. The

    trophic forms are often seen inclusters.

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    5/20

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    6/20

    A Giemsa stain for trophic forms (formerly called trophozoites) shows dot-

    like nuclei and pale blue cytoplasm (right arrow). The spore cases (formerly

    cysts) do not stain, but the intracystic bodies (formerly sporozoites) do (left

    arrow). Two alveolar macrophages indicate the relative sizes of organismsand cells.

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    7/20

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    8/20

    Patient with Pneumocyst is j i rovec i pneumon ia. Photom icrograph of lungbiopsy specimen (Gomori methenamine silver, 600) shows multiple small blackorganisms (arrowheads ) typical o f P. jiro veci. (

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    9/20

    Gomori methenamine silver stain

    This stain, often abbreviated as "GMS", is used to stain for fungi and for

    Pneumocy st is j i roveci (car ini i ). The cell walls of these organisms are

    stained, so the organisms are outlined by the brown to black stain. There

    is a tendency for this stain to produce a lot of artefact from background

    staining, so it is essential to be sure of the morphology of the organism

    being sought.

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    10/20

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    11/20

    E: Direct immunofluorescence antibody stain using monoclonal

    antibodies that target Pneumocystis jirovecii

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    12/20

    Transmission

    ACQUIRED CONGENITAL

    TRANSMISSION-Respiratory droplet

    -Environment

    -Direct transmission

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    13/20

    No detailed knowledge of

    the lifecycle and the mode

    of replication has not been

    definitely established

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    14/20

    Life cycle

    Mode of infection: inhalation of

    mature cyst.Two forms: cyst and trophozoite

    Trophozoites are amoeboid inshape with on nucleus . mature cyst

    contain 8 trophozoites .

    Mature cyst inhaled rupture

    trophozoites multiply precyst

    cyst .

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    15/20

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    16/20

    CLINICAL FEATURES The disease produced by it is called P.carinii

    pneumonia(PCP) which is also called asinterstitial plasma cell pneumonia with

    massive lobar involvement

    Symptoms : fever, cough, shortness of

    breath Extrapulmonary pneumocystosis is a rare

    event. In disseminated cases, liver,

    heart,kidney,spleen,bone marrow pancreas,

    stomach,thyroid and adrenal gland may also

    be affected.

    The presence of cotton wool spots in the

    fundus of the eye (bukti paling kukuh

    pendiagnosan)

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    17/20

    Laboratory findings NON SPECIFIC& SPECIFIC

    1. ESR

    - Raised level (inflammation)

    2. CRP C-Reactive Protein (bind to phosphocholine expressed

    on the surface of dead or dying cells)

    - Raised

    3.ANEMIA,LEUKOPENIA, THROMBOCYTOPENIA occurs

    4. X-RAY

    - Diffuse mottling of lung field

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    18/20

    5. PULMONARY FUNCTION TEST

    - Reduction in vital capacity of total lung capacity

    6. Gallium lung scanning

    7. Histopathology examination of lung biopsy

    - Alveoli filled with granular, foamy honeycomb like

    acellular material, infiltrate with mononuclear

    cells

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    19/20

    SPECIFIC DEMONSTRATION OF CYSTS

    In sputum, trancheobronchial lavage or tracheobronchial

    lavage or open lung biopsy. Cysts can be stained with

    Geimsa or Methanamine-Silver Techniqueor Gromori-

    methenamine Silver ((stained black)

    IMMUNOFLUORESENCE TEST

    DETECTION OF ANTIGEN OR ANTIBODIES

    - Monoclonal antibodies for direct detection of organisms in

    clinical specimens not available and appear to be very

    specific and sensitive

    CULTURE

    - Limited success.

  • 8/22/2019 Pneumocystis Cariinii 29 2 2013

    20/20

    Treatments

    Trimethoprim-sulfamethoxazole (TMP-SMZ)

    Pentamidine isethionate inhalant

    Treatments can be toxic and patient mustbe monitored closely

    Prophylactic treatment if CD4 count is low

    HAART(Highly Active Anti-RetroviralTherapy) regimen to boost immunesystem function, corticosteroids